Literature DB >> 9355977

Alterations and prognostic significance of p16 and p53 protein expression in subgroups of cutaneous melanoma.

O Straume1, L A Akslen.   

Abstract

The role of p16 and p53 alterations in cutaneous melanoma has been recently discussed, but it remains to be clarified. In the present immunohistochemical study, the expression of p16 and p53 proteins and their possible prognostic relevance have been examined in 102 melanomas of the aggressive nodular type. Twelve percent showed a strong expression of p53 protein, and these cases were significantly more frequent in the head/neck area compared with other sites (32% vs. 6%). Expression of p16 protein was negative or weak in 9% of the cases, and this tended to be less frequent in head/neck tumors compared with the others (0% vs. 12%). Whereas p53 staining was not prognostically important, loss of p16 staining was significantly associated with markedly reduced recurrence free and patient survival in univariate analysis (product-limit method). In multivariate analysis, lack of p16 staining was significantly associated with recurrent disease (p = 0.013). Our findings indicate an important role of altered p16 protein expression in a subgroup of melanoma patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9355977     DOI: 10.1002/(sici)1097-0215(19971021)74:5<535::aid-ijc10>3.0.co;2-5

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  24 in total

1.  Prognostic significance of regulators of cell cycle and apoptosis, p16(INK4a), p53, and bcl-2 in primary mucosal melanomas of the head and neck.

Authors:  Manju L Prasad; Snehal G Patel; Jatin P Shah; Stacy Hoshaw-Woodard; Klaus J Busam
Journal:  Head Neck Pathol       Date:  2011-12-13

2.  Trends in the diagnosis and clinical features of melanoma in situ (MIS) in US men and women: A prospective, observational study.

Authors:  Erin X Wei; Abrar A Qureshi; Jiali Han; Tricia Y Li; Eunyoung Cho; Jennifer Y Lin; Wen-Qing Li
Journal:  J Am Acad Dermatol       Date:  2016-07-16       Impact factor: 11.527

3.  Immunohistochemical expression of p16, p21, p27 and cyclin D1 in oral nevi and melanoma.

Authors:  Bruno Augusto Benevenuto de Andrade; Jorge Esquiche León; Román Carlos; Wilson Delgado-Azañero; Adalberto Mosqueda-Taylor; Oslei Paes de Almeida
Journal:  Head Neck Pathol       Date:  2012-02-05

Review 4.  Molecular pathogenesis of sporadic melanoma and melanoma-initiating cells.

Authors:  Yunyi Kong; Suresh M Kumar; Xiaowei Xu
Journal:  Arch Pathol Lab Med       Date:  2010-12       Impact factor: 5.534

Review 5.  Tailoring to RB: tumour suppressor status and therapeutic response.

Authors:  Erik S Knudsen; Karen E Knudsen
Journal:  Nat Rev Cancer       Date:  2008-09       Impact factor: 60.716

6.  QSOX1 expression is associated with aggressive tumor features and reduced survival in breast carcinomas.

Authors:  Gøril Knutsvik; Karin Collett; Jarle Arnes; Lars A Akslen; Ingunn M Stefansson
Journal:  Mod Pathol       Date:  2016-08-26       Impact factor: 7.842

7.  Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma.

Authors:  Rita G Ladstein; Ingeborg M Bachmann; Oddbjørn Straume; Lars A Akslen
Journal:  BMC Cancer       Date:  2010-04-14       Impact factor: 4.430

Review 8.  Melanoma biomarkers: current status and vision for the future.

Authors:  Allison R Larson; Eliz Konat; Rhoda M Alani
Journal:  Nat Clin Pract Oncol       Date:  2008-12-23

Review 9.  Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis.

Authors:  Bonnie E Gould Rothberg; Michael B Bracken; David L Rimm
Journal:  J Natl Cancer Inst       Date:  2009-03-24       Impact factor: 13.506

10.  Tumor necrosis is associated with increased alphavbeta3 integrin expression and poor prognosis in nodular cutaneous melanomas.

Authors:  Ingeborg M Bachmann; Rita G Ladstein; Oddbjørn Straume; George N Naumov; Lars A Akslen
Journal:  BMC Cancer       Date:  2008-12-05       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.